Androgen-responsive serum response factor target genes regulate prostate cancer cell migration

Carcinogenesis

Volumn 34, Issue 8, 2013, Pages 1737-1746

  Verone, Alissa R ^a   Duncan, Kelly ^a   Godoy, Alejandro ^a   Yadav, Neelu ^a   Bakin, Andrei ^a   Koochekpour, Shahriar ^a   Jin, Jian Ping ^b   Heemers, Hannelore V ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; BETA1 INTEGRIN; CALPONIN; CALPONIN 2; CELL ADHESION MOLECULE; SERUM RESPONSE FACTOR; SIDEKICK HOMOLOG 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ACTIN FILAMENT; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER GROWTH; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; CYTOSKELETON; DISEASE COURSE; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEPLETION;

EID: 84881488284     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt126     Document Type: Article

References (55)

1. Miyamoto, H. et al. (2004) Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate, 61, 332-353.
2. Ryan, C.J. et al. (2011) Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J. Clin. Oncol., 29, 3651-3658.
3. de Bono, J.S. et al.; COU-AA-301 Investigators. (2011) Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med., 364, 1995-2005.
4. Scher, H.I. et al.; AFFIRM Investigators. (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med., 367, 1187-1197.
5. Ryan, C.J. et al.; COU-AA-302 Investigators. (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med., 368, 138-148.
6. Cai, C. et al. (2011) Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res., 71, 6503-6513.
7. Mostaghel, E.A. et al. (2011) Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin. Cancer Res., 17, 5913-5925.
8. Richards, J. et al. (2012) Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res., 72, 2176-2182.
9. Heemers, H.V. et al. (2007) Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for Serum Response Factor in prostate cancer. Cancer Res., 67, 10592-10599.
10. Heemers, H.V. et al. (2011) Identification of a clinically relevant androgen- dependent gene signature in prostate cancer. Cancer Res., 71, 1978-1988.
11. Shore, P. et al. (1995) The MADS-box family of transcription factors. Eur. J. Biochem., 229, 1-13.
12. Sun, Q. et al. (2006) Defining the mammalian CArGome. Genome Res., 16, 197-207.
13. Miano, J.M. (2003) Serum Response Factor toggling between disparate programs of gene expression. J. Mol. Cell. Cardiol., 35, 577-593.
14. Miano, J.M. et al. (2007) Serum Response Factor master regulator of the actin cytoskeleton and contractile apparatus. Am. J. Physiol. Cell Physiol., 292, C70-C81.
15. Cooper, S.J. et al. (2007) Serum Response Factor binding sites differ in three human cell types. Genome Res., 17, 136-144.
16. Sun, Q. et al. (2009) Myocardin-dependent activation of the CArG box-rich smooth muscle gamma-actin gene: preferential utilization of a single CArG element through functional association with the NKX3.1 homeodomain protein. J. Biol. Chem., 284, 32582-32590.
17. Sullivan, A.L. et al. (2011) Serum Response Factor utilizes distinct promoter- and enhancer-based mechanisms to regulate cytoskeletal gene expression in macrophages. Mol. Cell. Biol., 31, 861-875.
18. Schmidt, L.J. et al. (2012) RhoA as a mediator of clinically relevant androgen action in prostate cancer cells. Mol. Endocrinol., 26, 716-735.
19. Treisman, R. (1987) Identification and purification of a polypeptide that binds to the c-fos serum response element. EMBO J., 6, 2711-2717.
20. Miano, J.M. (2010) Role of Serum Response Factor in the pathogenesis of disease. Lab. Invest., 90, 1274-1284.
21. Medjkane, S. et al. (2009) Myocardin-related transcription factors and SRF are required for cytoskeletal dynamics and experimental metastasis. Nat. Cell Biol., 11, 257-268.
22. Park, M.Y. et al. (2007) Expression of the Serum Response Factor in hepatocellular carcinoma: implications for epithelial-mesenchymal transition. Int. J. Oncol., 31, 1309-1315.
23. Kim, H.J. et al. (2009) The expression and role of serum response factor in papillary carcinoma of the thyroid. Int. J. Oncol., 35, 49-55.
24. Choi, H.N. et al. (2009) Serum response factor enhances liver metastasis of colorectal carcinoma via alteration of the E-cadherin/beta-catenin complex. Oncol. Rep., 21, 57-63.
25. Bai, S. et al. (2009) MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J. Biol. Chem., 284, 32015-32027.
26. Yu, W. et al. (2011) FGFR-4 Arg388 enhances prostate cancer progression via extracellular signal-related kinase and Serum Response Factor signaling. Clin. Cancer Res., 17, 4355-4366.
27. Murillo, H. et al. (2001) Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology, 142, 4795-4805.
28. Hossain, M.M. et al. (2003) Developmentally regulated expression of calponin isoforms and the effect of h2-calponin on cell proliferation. Am. J. Physiol. Cell Physiol., 284, C156-C167.
29. Luo, J. et al. (2001) Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res., 61, 4683-4688.
30. Vanaja, D.K. et al. (2003) Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res., 63, 3877-3882.
31. Lapointe, J. et al. (2004) Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl. Acad. Sci. U. S. A., 101, 811-816.
32. Dhanasekaran, S.M. et al. (2005) Molecular profiling of human prostate tissues: insights into gene expression patterns of prostate development during puberty. FASEB J., 19, 243-245.
33. Taylor, B.S. et al. (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell, 18, 11-22.
34. Varambally, S. et al. (2005) Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell, 8, 393-406.
35. Tomlins, S.A. et al. (2007) Integrative molecular concept modeling of prostate cancer progression. Nat. Genet., 39, 41-51.
36. Heinlein, C.A. et al. (2004) Androgen receptor in prostate cancer. Endocr. Rev., 25, 276-308.
37. Heemers, H.V. et al. (2007) Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr. Rev., 28, 778-808.
38. Verhoeven, G. et al. (1999) Indirect mechanisms and cascades of androgen action. Mol. Cell. Endocrinol., 151, 205-212.
39. Heemers, H.V. et al. (2006) Androgen activation of the sterol regulatory element-binding protein pathway: Current insights. Mol. Endocrinol., 20, 2265-2277.
40. Kalluri, R. et al. (2009) The basics of epithelial-mesenchymal transition. J. Clin. Invest., 119, 1420-1428.
41. Rathinam, R. et al. (2010) Important role of integrins in the cancer biology. Cancer Metastasis Rev., 29, 223-237.
42. Scales, T.M. et al. (2011) Spatial and temporal regulation of integrin signalling during cell migration. Curr. Opin. Cell Biol., 23, 562-568.
43. Hu, S. et al. (2010) Prosaposin down-modulation decreases metastatic prostate cancer cell adhesion, migration, and invasion. Mol. Cancer, 9, 30.
44. Wu, H.C. et al. (1994) Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int. J. Cancer, 57, 406-412.
45. Gorlov, I.P. et al. (2010) Prioritizing genes associated with prostate cancer development. BMC Cancer, 10, 599.
46. Siegel, R. et al. (2012) Cancer statistics, 2012. CA. Cancer J. Clin., 62, 10-29.
47. Attard, G. et al. (2011) Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients. Clin. Cancer Res., 17, 3867-3875.
48. North, A.J. et al. (1994) Calponin is localised in both the contractile apparatus and the cytoskeleton of smooth muscle cells. J. Cell Sci., 107 (Pt 3), 437-444.
49. Wu, K.C. et al. (2008) Calponin in non-muscle cells. Cell Biochem. Biophys., 52, 139-148.
50. Ramaswamy, S. et al. (2003) A molecular signature of metastasis in primary solid tumors. Nat. Genet., 33, 49-54.
51. Kaufman, L. et al. (2004) Sidekick-1 is upregulated in glomeruli in HIVassociated nephropathy. J. Am. Soc. Nephrol., 15, 1721-1730.
52. Kaufman, L. et al. (2010) Up-regulation of the homophilic adhesion molecule sidekick-1 in podocytes contributes to glomerulosclerosis. J. Biol. Chem., 285, 25677-25685.
53. Nagle, R.B. et al. (2011) Metastasis Update: Human Prostate Carcinoma Invasion via Tubulogenesis. Prostate Cancer, 2011, 249290.
54. Brandt, D.T. et al. (2009) SCAI acts as a suppressor of cancer cell invasion through the transcriptional control of beta1-integrin. Nat. Cell Biol., 11, 557-568.
55. Lener, T. et al. (2004) The role of calponin in the gene profile of metastatic cells: inhibition of metastatic cell motility by multiple calponin repeats. FEBS Lett., 556, 221-226.